| Sarah Elizabeth Novak, | |
|
59 Hospital Rd # 1209, Newnan, GA 30263-1209 | |
| (678) 423-4610 | |
| Not Available |
| Full Name | Sarah Elizabeth Novak |
|---|---|
| Gender | Female |
| Speciality | Social Worker |
| Location | 59 Hospital Rd # 1209, Newnan, Georgia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003459843 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | (* (Not Available)) | Secondary |
| 104100000X | Social Worker | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Elizabeth Novak, 122 Gordon Commercial Dr Ste C, Lagrange, GA 30240-5754 Ph: (706) 845-4045 | Sarah Elizabeth Novak, 59 Hospital Rd # 1209, Newnan, GA 30263-1209 Ph: (678) 423-4610 |
News Archive
The University of Michigan Medical School will greatly expand and improve its space and technology for training future physicians, with a $55 million project approved by the U-M Board of Regents today.
"Over the next few weeks, appropriators will be engaged in the challenging task of evaluating U.S. foreign assistance funding, including how effectively Congress' global health investments are being used," Charles Lyons, president and CEO of the Elizabeth Glaser Pediatric AIDS Foundation; Molly Joel Coye, interim president and CEO of PATH; Carolyn Miles, president and CEO of Save the Children; and Richard Stearns, president of World Vision, write in this Roll Call opinion piece.
Researchers are only beginning to understand how individual variation in gene regulation can have a lasting impact on one's health and susceptibility to certain diseases. Now, an ambitious survey of the human genome has identified differences in the binding of master regulators called transcription factors to DNA that affect how genes are expressed in different people.
The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention. This is the first intrauterine device approved by the FDA for this additional indication.
A recent study published in Pacing and Clinical Electrophysiology (PACE) determined that the use of catheter ablation to treat supraventricular tachycardia (SVT) is not detrimental to patients.
› Verified 3 days ago